Plasmacytoma
Drug research and approvals for plasmacytoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 17 studies of plasmacytoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 17
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory…NCT07777406 · Not reported · Università degli Studi 'G. d'Annunzio' Chieti e Pescara · starts Mar 24, 2026
- In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell NeoplasmsNCT07586709 · Early Phase 1 · Liping Dou · starts May 9, 2026
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaNCT07529782 · Phase 1 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · starts Mar 17, 2026
- CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell NeoplasmsNCT07519187 · Early Phase 1 · The General Hospital of Western Theater Command · starts Apr 23, 2026
- CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell NeoplasmsNCT07416682 · Early Phase 1 · Affiliated Hospital to Academy of Military Medical Sciences · starts Apr 14, 2026
- 68Ga-BCMA PET/CT in Multiple MyelomaNCT07319897 · Phase 2 / Phase 3 · Peking University First Hospital · starts Dec 25, 2025
- A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell…NCT07179679 · Phase 1 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · starts Dec 9, 2025
- Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow…NCT07115667 · Phase 2 · Institute of Hematology & Blood Diseases Hospital, China · starts Aug 25, 2025
- Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms…NCT07085559 · Early Phase 1 · Anhui Provincial Hospital · starts Jun 23, 2025
Phase 3 5
- DexamethasoneGlucocorticoid receptor agonist
- LenalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- Bortezomib26S proteasome inhibitor
- Zoledronic acidFarnesyl diphosphate synthase inhibitor
- Ixazomib26S proteasome inhibitor
Phase 2 6
- BusulfanDNA inhibitor
- PanobinostatHistone deacetylase inhibitor
- PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- CyclophosphamideDNA inhibitor
- DaratumumabLymphocyte differentiation antigen CD38 inhibitor
Phase 1 or earlier 5
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- Carfilzomib26S proteasome inhibitor
- DurvalumabProgrammed cell death 1 ligand 1 inhibitor
- MilatuzumabHLA-DR antigens-associated invariant chain antagonist
- NavtemadlinTumour suppressor p53/oncoprotein Mdm2 inhibitor
How its trials ended
363 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 104 whose ending is known, 26% met their primary endpoint, 7% missed it and 67% stopped early.
- Completed, result not reported21459%
- Status unknown308%
- Stopped: other or unclear298%
- Stopped: enrollment or feasibility288%
- Met its primary endpoint277%
- Ongoing154%
- Missed its primary endpoint72%
- Stopped: sponsor or business decision62%
- Stopped: funding41%
- Stopped: lack of efficacy21%
- Stopped: safety1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA